FDA clears test to detect antibodies to HMGCR
September 2018—Inova Diagnostics announced FDA clearance of its Quanta Flash HMGCR for use on its Bio-Flash random access chemiluminescent system.
Webinars and Sponsored Roundtables — Register Now
Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
Beckman releases DxM MicroScan
September 2018—Beckman Coulter announced commercialization of its DxM MicroScan WalkAway system, a diagnostic solution for bacterial identification and antibiotic susceptibility testing that uses direct minimum inhibitory concentrations for detection of antimicrobial resistance.
FDA expands use of Novartis’ Kisqali
September 2018—Novartis announced FDA approval for Kisqali (ribociclib) for women with hormone-receptor positive, human epidermal growth factor receptor-2 negative advanced or metastatic breast cancer.
TORCH panel antigens
September 2018—Binding Site’s Immunologicals Group announced a line of highly purified TORCH antigens for use in in vitro diagnostic manufacturing and research applications.
SureSeq NGS analysis software
September 2018—Oxford Gene Technology launched its SureSeq Interpret software, designed to be used with SureSeq NGS panels, to analyze and visualize a range of mutation types and structural variants. The software rapidly processes sequencing data and delivers accurate mutation calling with 100 percent sensitivity and 99.9 percent specificity at >1 percent variant allele frequency.
CLSI publishes new method evaluation guideline
September 2018—The Clinical and Laboratory Standards Institute announced the publication of “EP34—Establishing and Verifying an Extended Measuring Interval Through Specimen Dilution and Spiking, 1st ed.” EP34 provides recommendations for establishing a dilution scheme to be used for patient specimens that contain measurand concentrations in the extended measuring interval above a measurement procedure’s upper limit of quantitation.
Validate IBC for Ortho Vitros analyzers
September 2018—LGC Maine Standards’ Validate IBC linearity and calibration verification kit for Ortho Vitros analyzers is now available. The liquid, ready-to-use kit, in a human serum matrix, evaluates total iron binding capacity.
APPIA seeking new members
September 2018—The Anatomical Pathology Patient Interest Association, a nonprofit professional membership organization focused on advancing patient safety, quality, standards, and accessibility of care in anatomical pathology, is looking for new members.
Qiagen partners with Health Innovation Manchester
September 2018—Qiagen announced a partnership with multiple organizations to support creating a worldwide genomics campus in Manchester, U.K., for innovation, life sciences, translational science, and molecular diagnostics. Qiagen is working with Health Innovation Manchester to bring together public, academic, and clinical resources to develop the Genomic Health Innovation Campus, anchored by Qiagen’s European Centre of Excellence for Precision Medicine and hub for diagnostics development.
Agilent acquires ProZyme, Ultra Scientific
September 2018—Agilent Technologies has entered into a definitive agreement to acquire ProZyme, a provider of glycan analysis reagents, kits, and standards. The acquisition will expand Agilent’s portfolio of biopharma consumables.